QUICK ANSWER · AEO / GEO
A peptide associated with sleep research, but identity, study quality and clinical evidence remain limited and uncertain.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- confirmed endogenous gene, precursor, receptor and physiological role
- human pharmacokinetics and bioavailability across proposed routes
- long-term safety, immunogenicity, reproductive safety and rare adverse events
- clinically meaningful benefit in modern insomnia populations
- efficacy for narcolepsy or opioid withdrawal
- current product-specific regulatory status outside the reviewed FDA compounding process
What limits these conclusions?
- The human literature is old, small and predominantly intravenous, while current commercial discussion often concerns other routes. Positive studies used few participants; the 16-person chronic-insomnia trial found weak and inconsistent effects. The endogenous identity and receptor remain unresolved. FDA also found route mismatch, naming complexity, insufficient effectiveness and limited safety information.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.accessdata.fda.gov/scripts/cder/daf/
- https://www.ema.europa.eu/en/medicines
- https://www.fda.gov/media/193344/download
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://precision.fda.gov/uniisearch/srs/unii/YN28Z5YZ73
- https://pubmed.ncbi.nlm.nih.gov/6895513/
- https://pubmed.ncbi.nlm.nih.gov/6112579/
- https://pubmed.ncbi.nlm.nih.gov/1299794/
- https://pubmed.ncbi.nlm.nih.gov/2554357/
- https://pubmed.ncbi.nlm.nih.gov/568769/
- https://pubmed.ncbi.nlm.nih.gov/590449/
- https://pubmed.ncbi.nlm.nih.gov/16539679/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is DSIP (Emideltide)?
DSIP (Emideltide) is described pharmacologically as Experimental nonapeptide historically studied in sleep and neuroendocrine research. A peptide associated with sleep research, but identity, study quality and clinical evidence remain limited and uncertain.
Does DSIP (Emideltide) have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is DSIP (Emideltide) approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.